# A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients

> **NCT02446145** · PHASE2 · TERMINATED · sponsor: **Technische Universität Dresden** · enrollment: 132 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Eltrombopag
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02446145
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2020-12-26
- **Final completion:** 2023-01-25
- **Target enrollment:** 132 (ACTUAL)
- **Why stopped:** Due to COVID-19 pandemia, recruitment was insufficient to reach required sample size in an acceptable time line. Furthermore, new drugs have recently been licensed resulting in alternative treatment regimens with a better prognosis.
- **Last updated:** 2024-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02446145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02446145, "A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02446145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*